Atlanta based GeoVax Labs has inoculated its first human patient of its HIV vaccine.
The inoculation comes after successful tests on other primates.
The vaccine is designed to control the spread of HIV in the body.
Dosing the first study participant marks a major milestone for our Phase 1/2 clinical trial. We are pleased to have the AIDS Research Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama, Birmingham, and the AIDS Research Alliance of Los Angeles participating in the trial.
These three sites are currently seeking study participants.
The fight against HIV continues to move forward in the right direction.
However, everyone needs to continue to be safe out there!